A^1, A^2, and A^3 are each independently selected from the group consisting of N, CH and $C(R^{4a})$, provided that at least one of A^1, A^2, or A^3 is N and no more than two of A^1, A^2, or A^3 are N;

each R^{4a} is independently selected from the group consisting of halogen, -C_{1-4} alkyl, -C_{1-4} alkoxy, and -CN;

R^{1a} is selected from the group consisting of -C_{3-10} cycloalkyl, -C_{1-4} alkyl-C_{3-10} cycloalkyl, -C_{6-10} aryl, and -C_{1-4} alkyl-C_{6-10} aryl, wherein said cycloalkyl, alkylcycloalkyl, aryl, and alkylaryl groups are optionally substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halogen, hydroxy, -CN, -ORb^a, -SRb^a, -$N(Rb^a)_2$, -C_{1-4} alkyl optionally substituted with 1, 2, or 3 halogen atoms, optionally substituted -C_{6-10} aryl, optionally substituted -(5- to 10-membered)-C_{1-9} heteroaryl, -(5- to 10-membered)-C_{2-9} heterocyclyl, and optionally substituted –O-(C_{6-10} aryl); and wherein said cycloalkyl, alkylcycloalkyl, aryl, and alkylaryl is optionally fused to a further (second) ring; and







R^{2a} is selected from the group consisting of hydrogen and -C_{1-4} alkyl, wherein said -C_{1-4} alkyl is optionally substituted; or

R^{1a} and R^{2a} together with the nitrogen atom to which they are attached form an optionally substituted 5- to 6-membered heterocyclic ring, wherein said heterocyclic ring optionally contains 1, 2, or 3 additional heteroatoms selected from the group consisting of N, S, or O, and wherein said heterocyclic ring is optionally fused to a phenyl ring;

each Rb^a is independently hydrogen, -C_{1-4} alkyl, -C_{3-10} cycloalkyl, or -(5- to 10-membered)-C_{2-9} heterocyclyl, wherein said alkyl, cycloalkyl or heterocyclyl group is optionally substituted by 1, 2 or 3 fluorine atoms; and

R^{3a} is selected from the group consisting of -C_{6-10} aryl, -(5- to 10-membered)-C_{1-9} heteroaryl, and -C_{3-10} cycloalkyl, wherein said aryl, heteroaryl, and cycloalkyl groups are optionally substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halogen, hydroxy, -CN, -ORb^a, -SRb^a, -$N(Rb^a)_2$, -C_{1-4}alkyl optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of halogen, -CN, -ORb^a, and -$N(Rb^a)_2$, optionally substituted -C_{6-10} aryl, optionally substituted -(5- to 10-membered)-C_{1-9} heteroaryl and -(5- to 10-membered)-C_{2-9} heterocyclyl, and wherein said -C_{6-10} aryl is optionally fused to a 5- or 6-membered heterocyclic.

In another aspect, the present disclosure refers to a compound, which is selected from the group consisting of


,

,

,

,

, and


or a pharmaceutically aceptable salt or solvate thereof.

In a further aspect, the present disclosure refers to a pharmaceutical composition, comprising a compound as disclosed herein, or a pharmaceutically acceptable salt or solvate thereof, and at least one pharmaceutically acceptable excipient.

In another aspect, the present disclosure refers to a compound as disclosed herein for use as a medicament.

In yet another aspect, the present disclosure refers to a compound as disclosed herein

(a) for use in the treatment or prevention of a lysosomal storage disease;

(b) for use in the treatment or prevention of an α-synucleinopathy; or

(c) for use in the treatment or prevention of a disease or disorder, wherein said disease or disorder is selected from the group consisting of: Gaucher's disease, Parkinson’s disease, dementia with Lewy bodies, diffuse Lewy body disease, multiple system atrophy (MSA), epilepsy, bipolar disorder, schizophrenia, an anxiety disorder, major depression, polycystic kidney disease, type 2 diabetes, open angle glaucoma, multiple sclerosis (MS), multiple myeloma, Alzheimer's disease, amyothophic lateral sclerosis (ALS), corticobasal degeneration, frontotemporal lobe dementia, GBA1 Parkinson, neuronopathic Gaucher's disease, neuroaxonal dystrophy, neurodegenerative diseases with parkinsonism, progressive supranuclear palsy, pure autonomic failure, sporadic Creuzfeldt-Jakob disease, and unimpaired aging.

In a further aspect, the present disclosure refers to a use of a compound as disclosed herein

(a) in the manufacture of a medicament for the treatment or prevention of a lysosomal storage disease;

(b) in the manufacture of a medicament for the treatment or prevention of an α-synucleinopathy; or

(c) in the manufacture of a medicament for the treatment or prevention of a disease or disorder selected from the group consisting of: Gaucher's disease, Parkinson’s disease, dementia with Lewy bodies, diffuse Lewy body disease, multiple system atrophy (MSA), epilepsy, bipolar disorder, schizophrenia, an

anxiety disorder, major depression, polycystic kidney disease, type 2 diabetes, open angle glaucoma, multiple sclerosis (MS), multiple myeloma, Alzheimer's disease, amyothophic lateral sclerosis (ALS), corticobasal degeneration, frontotemporal lobe dementia, GBA1 Parkinson, neuronopathic Gaucher's disease, neuroaxonal dystrophy, neurodegenerative diseases with parkinsonism, progressive supranuclear palsy, pure autonomic failure, sporadic Creuzfeldt-Jakob disease, and unimpaired aging.

In another aspect, the present disclosure refers to a pharmaceutical composition as disclosed herein for use as a medicament.

In yet another aspect, the present disclosure refers to a pharmaceutical composition as disclosed herein (a) for use in the treatment or prevention of a lysosomal storage disease; (b) for use in the treatment or prevention of an α-synucleinopathy; or (c) for use in the treatment or prevention of a disease or disorder, wherein said disease or disorder is selected from the group consisting of: Gaucher's disease, Parkinson’s disease, dementia with Lewy bodies, diffuse Lewy body disease, multiple system atrophy (MSA), epilepsy, bipolar disorder, schizophrenia, an anxiety disorder, major depression, polycystic kidney disease, type 2 diabetes, open angle glaucoma, multiple sclerosis (MS), multiple myeloma, Alzheimer's disease, amyothophic lateral sclerosis (ALS), corticobasal degeneration, frontotemporal lobe dementia, GBA1 Parkinson, neuronopathic Gaucher's disease, neuroaxonal dystrophy, neurodegenerative diseases with parkinsonism, progressive supranuclear palsy, pure autonomic failure, sporadic Creuzfeldt-Jakob disease, and unimpaired aging.

In a further aspect, the present disclosure refers to a use of a pharmaceutical composition as disclosed herein in the manufacture of a medicament (a) for the treatment or prevention of a lysosomal storage disease; (b) for the treatment or prevention of an α-synucleinopathy; or (c) for the treatment or prevention of a disease or disorder, wherein said disease or disorder is selected from the group consisting of: Gaucher's disease, Parkinson’s disease, dementia with Lewy bodies, diffuse Lewy body disease, multiple system atrophy (MSA), epilepsy, bipolar disorder, schizophrenia, an anxiety disorder, major depression, polycystic kidney disease, type 2 diabetes, open angle glaucoma, multiple sclerosis (MS), multiple myeloma, Alzheimer's disease, amyothophic lateral sclerosis (ALS), corticobasal degeneration, frontotemporal lobe dementia, GBA1 Parkinson, neuronopathic

Gaucher's disease, neuroaxonal dystrophy, neurodegenerative diseases with parkinsonism, progressive supranuclear palsy, pure autonomic failure, sporadic Creuzfeldt-Jakob disease, and unimpaired aging.

In one example, the present disclosure provides compounds represented by formulae (IA) and (IB) below, and pharmaceutically acceptable salts and solvates thereof, collectively referred to herein as "Compounds of the Disclosure" (each is individually referred to hereinafter as a "Compound of the Disclosure").

In another example, the present disclosure provides a method of treating or preventing a condition associated with the alteration of the activity of β-glucocerebrosidase in a patient in need thereof. The method comprises administering to the patient in need thereof an effective amount of a Compound of the Disclosure.

As used herein, the terms "heterocyclyl" or "heterocyclic group" embrace typically a monocyclic or polycyclic, non-aromatic, saturated or unsaturated C_{2-10} carbocyclic ring, such as a 5- to 10-membered radical, in which one or more, for example 1, 2, 3 or 4 of the carbon atoms, for example, 1 or 2 of the carbon atoms are replaced by a heteroatom selected from N, O and S. In one embodiment, the heterocyclyl is a C_{3-7} heterocyclyl, i.e., a heterocycle having 3-7 carbon atoms and at least one heteroatom. In another embodiment, a heterocyclyl is a (5- to 10-membered)-C_{2-9} heterocyclyl, i.e., a heterocycle having 5- to 10-members, of which 2-9 members are carbon. In another embodiment, the heteroatom is N. In another embodiment, the heteroatom is O.

In another embodiment, the heterocyclyl radicals are saturated. A heterocyclic radical can be a single ring or two or more fused rings wherein at least one ring contains a heteroatom. When a heterocyclyl radical carries one or more substituents, the substituents can be the same or different.


A said optionally substituted heterocyclyl is typically unsubstituted or substituted with 1, 2 or 3 substituents which can be the same or different. Examples of heterocyclic radicals include piperidyl, pyrrolidyl, pyrrolinyl, piperazinyl, morpholinyl, thiomorpholinyl, pyrazolinyl, pyrazolidinyl, quinuclidinyl, cromanyl, isocromanyl, imidazolidinyl, oxiranyl, azaridinyl, 4,5-dihydro-oxazolyl and 3-aza-tetrahydrofuranyl. The substituents are, for example, selected from halogen atoms, for example, fluorine or chlorine atoms, hydroxy groups, alkoxycarbonyl groups in which the alkyl moiety has from 1 to 4 carbon atoms, hydroxycarbonyl groups, carbamoyl groups, nitro groups, cyano groups, C_{1-4} alkyl groups optionally substituted by one or more halogen atoms, C_{1-4} alkoxy groups, optionally substituted by one or more halogen atoms and C_{1-4} hydroxyalkyl groups.

As used herein, the term "alkylheterocyclyl" when employed in the definition of a substituent refers to a heterocyclyl group as defined above which is linked through an alkylene radical with the core structure which it substitutes. In one embodiment, the alkylheterocyclyl is a -C_{1-4} alkyl-(5- to 10-membered)-C_{2-9} heterocyclyl.

As used herein, the term "aryl" designates typically a C_{6-10} monocyclic or polycyclic aryl radical such as phenyl and naphthyl. In another embodiment, the aryl is phenyl. A said optionally substituted aryl radical is typically unsubstituted or substituted with 1, 2 or 3 substituents which can be the same or different. The substituents are, for example, selected from halogen atoms, for example, fluorine or chlorine atoms, hydroxy groups, alkoxycarbonyl groups in which the alkyl moiety has from 1 to 4 carbon atoms, hydroxycarbonyl groups, carbamoyl groups, nitro groups,

WHAT IS CLAIMED IS:

1. A compound of formula (IA):



(IA),

or a pharmaceutically acceptable salt or solvate thereof, wherein

A^1, A^2, and A^3 are each independently selected from the group consisting of N, CH and $C(R^{4a})$, provided that at least one of A^1, A^2, or A^3 is N and no more than two of A^1, A^2, or A^3 are N;

each R^{4a} is independently selected from the group consisting of halogen, -C_{1-4} alkyl, -C_{1-4} alkoxy, and -CN;

R^{1a} is selected from the group consisting of -C_{3-10} cycloalkyl, -C_{1-4} alkyl-C_{3-10} cycloalkyl, -C_{6-10} aryl, and -C_{1-4} alkyl-C_{6-10} aryl, wherein said cycloalkyl, alkylcycloalkyl, aryl, and alkylaryl groups are optionally substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halogen, hydroxy, -CN, -ORb^a, -SRb^a, -$N(Rb^a)_2$, -C_{1-4} alkyl optionally substituted with 1, 2, or 3 halogen atoms, optionally substituted -C_{6-10} aryl, optionally substituted -(5- to 10-membered)-C_{1-9} heteroaryl, -(5- to 10-membered)-C_{2-9} heterocyclyl, and optionally substituted –O-(C_{6-10} aryl); and wherein said cycloalkyl, alkylcycloalkyl, aryl, and alkylaryl is optionally fused to a further (second) ring; and

R^{2a} is selected from the group consisting of hydrogen and -C_{1-4} alkyl, wherein said -C_{1-4} alkyl is optionally substituted; or

R^{1a} and R^{2a} together with the nitrogen atom to which they are attached form an optionally substituted 5- to 6-membered heterocyclic ring, wherein said heterocyclic ring optionally contains 1, 2, or 3 additional heteroatoms selected from the group consisting of N, S, or O, and wherein said heterocyclic ring is optionally fused to a phenyl ring;

each Rb^a is independently hydrogen, -C_{1-4} alkyl, -C_{3-10} cycloalkyl, or -(5- to 10-membered)-C_{2-9} heterocyclyl, wherein said alkyl, cycloalkyl or heterocyclyl group is optionally substituted by 1, 2 or 3 fluorine atoms; and

R^{3a} is selected from the group consisting of -C_{6-10} aryl, -(5- to 10-membered)-C_{1-9} heteroaryl, and -C_{3-10} cycloalkyl, wherein said aryl, heteroaryl, and cycloalkyl groups are optionally substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halogen, hydroxy, -CN, -ORb^a, -SRb^a, -$N(Rb^a)_2$, -C_{1-4}alkyl optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of halogen, -CN, -ORb^a, and -$N(Rb^a)_2$, optionally substituted -C_{6-10} aryl, optionally substituted -(5- to 10-membered)-C_{1-9} heteroaryl and -(5- to 10-membered)-C_{2-9} heterocyclyl, and wherein said -C_{6-10} aryl is optionally fused to a 5- or 6-membered heterocyclic.

2. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein A^1 is N and A^2 and A^3 are each independently selected from the group consisting of CH and $C(R^{4a})$.

3. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein (i) A^2 is N and A^1 and A^3 are each independently selected from the group consisting of CH and $C(R^{4a})$; (ii) A^3 is N and A^1 and A^2 are each independently selected from the group consisting of CH and $C(R^{4a})$; (iii) A^1 and A^2 are both N and A^3 is CH or $C(R^{4a})$; (iv) A^1 and A^3 are both N and A^2 is CH or $C(R^{4a})$; or (v) A^2 and A^3 are both N and A^1 is CH or $C(R^{4a})$.

4. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt or solvate thereof, wherein R^{3a} is unsubstituted -C_{6-10} aryl or -C_{6-10} aryl substituted with 1 or 2 substituents each independently selected from the group consisting of halogen, hydroxy, -CN, -O(C_{1-4})alkyl, -S(C_{1-4})alkyl, -N(C_{1-4} alkyl)$_2$, -NH(C_{1-4} alkyl), and -C_{1-4} alkyl optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of halogen, -CN, -O(C_{1-4})alkyl, -N(C_{1-4} alkyl)$_2$, and -NH(C_{1-4} alkyl).

5. The compound of claim 4, wherein R^{3a} is phenyl substituted with 1 or 2 substituents each independently selected from the group consisting of F, CL, Br, I, hydroxy, methyl, methoxy, and –CN.

6. The compound of claim 5, wherein R^{3a} is phenyl substituted with F or hydroxy at the ortho- or meta-position of the phenyl ring.

7. The compound of any one of claims 1-3, wherein R^{3a} is unsubstituted -C_{6-10} aryl fused to a 5- or 6-membered heterocyclic ring.

8. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt or solvate thereof, wherein R^{3a} is unsubstituted –(5- to 10-membered)-C_{6-9} heteroaryl or –(5- to 10-membered)-C_{6-9} heteroaryl substituted with 1 or 2 substituents each independently selected from the group consisting of halogen, hydroxy, -CN, -O(C_{1-4})alkyl, -S(C_{1-4})alkyl, -N(C_{1-4} alkyl)$_2$, -NH(C_{1-4} alkyl), and -C_{1-4} alkyl optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of halogen, -CN, -O(C_{1-4})alkyl, -N(C_{1-4} alkyl)$_2$, and -NH(C_{1-4} alkyl).

9. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt or solvate thereof, wherein R^{3a} is unsubstituted –C_{3-10} cycloalkyl or -C_{3-10} cycloalkyl substituted with 1 or 2 substituents each independently selected from the group consisting of halogen, hydroxy, -CN, -O(C_{1-4})alkyl, -S(C_{1-4})alkyl, -N(C_{1-4} alkyl)$_2$, -NH(C_{1-4} alkyl), and -C_{1-4} alkyl optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of halogen, -CN, -O(C_{1-4})alkyl, -N(C_{1-4} alkyl)$_2$, and -NH(C_{1-4} alkyl).

10. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt or solvate thereof, wherein R^{2a} is H.

11. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt or solvate thereof, wherein R^{2a} is -C_{1-4} alkyl.

12. The compound of any one of claims 1-11, or a pharmaceutically acceptable salt or solvate thereof, wherein R^{1a} is -C_{6-10} aryl or -C_{1-4} alkyl-C_{6-10} aryl, wherein said aryl or alkylaryl is optionally substituted with 1, 2 or 3 groups each independently selected from the group consisting of halogen, hydroxy, -CN, -ORb^a, -SRb^a, -$N(Rb^a)_2$, -C_{1-4} alkyl optionally substituted with 1, 2, or 3 halogen atoms, optionally substituted -C_{6-10} aryl, optionally substituted -(5- to 10-membered)-C_{1-9} heteroaryl, and -(5- to 10-membered)-C_{2-9} heterocyclyl, wherein Rb^a is as defined in claim 1; and wherein said aryl is optionally fused to a further (second) ring.

13. The compound of any one of claims 1-12, or a pharmaceutically acceptable salt or solvate thereof, wherein R^{1a} is unsubstituted phenyl or unsubstituted benzyl.

14. The compound of any one of claims 1-12, wherein R^{1a} is phenyl fused to a 5- or 6-membered heterocyclic ring.

15. The compound of any one of claims 1-11, or a pharmaceutically acceptable salt or solvate thereof, wherein R^{1a} is –C_{3-10} cycloalkyl or -C_{1-4} alkyl-C_{3-10} cycloalkyl, wherein said cycloalkyl or alkylcycloalkyl is optionally substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halogen, hydroxy, -CN, -ORb^a, -SRb^a, -$N(Rb^a)_2$, -C_{1-4} alkyl optionally substituted with 1, 2, or 3 halogen atoms, optionally substituted -C_{6-10} aryl, optionally substituted -(5- to 10-membered)-C_{1-9} heteroaryl, and -(5- to 10-membered)-C_{2-9} heterocyclyl, wherein Rb^a is as defined in claim 1; and wherein said cycloalkyl is optionally fused to a further (second) ring.

16. The compound of any one of claims 1-11 or 15, or a pharmaceutically acceptable salt or solvate thereof, wherein R^{1a} is unsubstituted –C_{3-10} cycloalkyl fused to a phenyl ring.










17. The compound of claim 16, wherein R^{1a} is –C_{4-7} cycloalkyl fused to a phenyl ring.









18. The compound of any one of claims 1-17, or a pharmaceutically acceptable salt or solvate thereof, wherein Rb^a is hydrogen or -C_{1-4} alkyl.

19. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt or solvate thereof, wherein R^{1a} and R^{2a} together with the nitrogen atom to which they are attached form an optionally substituted 5- to 10-membered heterocyclic ring, wherein said heterocyclic ring optionally contains 1, 2, or 3 additional heteroatoms selected from the group consisting of N, S, or O, and wherein said heterocyclic ring is optionally fused to a phenyl ring.










20. The compound of claim 19, or a pharmaceutically acceptable salt or solvate thereof, wherein R^{1a} and R^{2a} together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocyclic ring optionally fused to a phenyl ring.


21. The compound of claim 1, which is selected from the group consisting of



,

,

,

,

,

,

,

,

,


























,

,

,

,

,

,

, and

, or a pharmaceutically acceptable salt or solvate thereof.

22. The compound of claim 1, which is selected from the group consisting of


,

,

,

,

,

,

,

,

,







,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,









,
5



or a pharmaceutically acceptable acceptable salt or solvate thereof.







23. The compound of claim 1, selected from the group consisting of










, and .

5

24. A compound, which is selected from the group consisting of






, and  or a pharmaceutically aceptable salt or solvate thereof.

25. A pharmaceutical composition, comprising a compound of any one of claims 1-24, or a pharmaceutically acceptable salt or solvate thereof, and at least one pharmaceutically acceptable excipient.

26. A compound of any one of claims 1-24 for use as a medicament.

27. A compound of any one of claims 1-24

(a) for use in the treatment or prevention of a lysosomal storage disease;

(b) for use in the treatment or prevention of an α-synucleinopathy; or

(c) for use in the treatment or prevention of a disease or disorder, wherein said disease or disorder is selected from the group consisting of: Gaucher's disease, Parkinson's disease, dementia with Lewy bodies, diffuse Lewy body disease, multiple system atrophy (MSA), epilepsy, bipolar disorder, schizophrenia, an anxiety disorder, major depression, polycystic kidney disease, type 2 diabetes, open angle glaucoma, multiple sclerosis (MS), multiple myeloma, Alzheimer's disease, amyothophic lateral sclerosis (ALS), corticobasal degeneration, frontotemporal lobe dementia, GBA1 Parkinson, neuronopathic Gaucher's disease, neuroaxonal dystrophy, neurodegenerative diseases with parkinsonism, progressive supranuclear palsy, pure autonomic failure, sporadic Creuzfeldt-Jakob disease, and unimpaired aging.

28. The compound for use as claimed in claim 27, wherein the lysosomal storage disease is Gaucher's disease.

29. Use of a compound of any one of claims 1-24

(a) in the manufacture of a medicament for the treatment or prevention of a lysosomal storage disease;

(b) in the manufacture of a medicament for the treatment or prevention of an α-synucleinopathy; or

(c) in the manufacture of a medicament for the treatment or prevention of a disease or disorder selected from the group consisting of: Gaucher's disease, Parkinson's disease, dementia with Lewy bodies, diffuse Lewy body disease, multiple system atrophy (MSA), epilepsy, bipolar disorder, schizophrenia, an anxiety disorder, major depression, polycystic kidney disease, type 2 diabetes, open angle glaucoma, multiple sclerosis (MS), multiple myeloma, Alzheimer's disease, amyothophic lateral sclerosis (ALS), corticobasal degeneration, frontotemporal lobe dementia, GBA1 Parkinson, neuronopathic Gaucher's disease, neuroaxonal dystrophy, neurodegenerative diseases with parkinsonism, progressive supranuclear palsy, pure autonomic failure, sporadic Creuzfeldt-Jakob disease, and unimpaired aging.

30. The use as claimed in claim 29, wherein the lysosomal storage disease is Gaucher's disease.

31. A pharmaceutical composition as defined in claim 25 for use as a medicament.

32. A pharmaceutical composition as defined in claim 25 (a) for use in the treatment or prevention of a lysosomal storage disease; (b) for use in the treatment or prevention of an α-synucleinopathy; or (c) for use in the treatment or prevention of a disease or disorder, wherein said disease or disorder is selected from the group consisting of: Gaucher's disease, Parkinson's disease, dementia with Lewy bodies, diffuse Lewy body disease, multiple system atrophy (MSA), epilepsy, bipolar disorder, schizophrenia, an anxiety disorder, major depression, polycystic kidney disease, type 2 diabetes, open angle glaucoma, multiple sclerosis (MS), multiple myeloma, Alzheimer's disease, amyothophic lateral sclerosis (ALS), corticobasal degeneration, frontotemporal lobe dementia, GBA1 Parkinson, neuronopathic Gaucher's disease, neuroaxonal dystrophy, neurodegenerative diseases with parkinsonism, progressive supranuclear palsy, pure autonomic failure, sporadic Creuzfeldt-Jakob disease, and unimpaired aging.

33. The pharmaceutical composition for use of claim 32, wherein said use is for the treatment or prevention of a lysosomal storage disease which is Gaucher's disease.

34. Use of a pharmaceutical composition as defined in claim 25 in the manufacture of a medicament (a) for the treatment or prevention of a lysosomal storage disease; (b) for the treatment or prevention of an α-synucleinopathy; or (c) for the treatment or prevention of a disease or disorder, wherein said disease or disorder is selected from the group consisting of: Gaucher's disease, Parkinson’s disease, dementia with Lewy bodies, diffuse Lewy body disease, multiple system atrophy (MSA), epilepsy, bipolar disorder, schizophrenia, an anxiety disorder, major depression, polycystic kidney disease, type 2 diabetes, open angle glaucoma, multiple sclerosis (MS), multiple myeloma, Alzheimer's disease, amyothophic lateral sclerosis (ALS), corticobasal degeneration, frontotemporal lobe dementia, GBA1 Parkinson, neuronopathic Gaucher's disease, neuroaxonal dystrophy, neurodegenerative diseases with parkinsonism, progressive supranuclear palsy, pure autonomic failure, sporadic Creuzfeldt-Jakob disease, and unimpaired aging.

35. The use of claim 34, wherein said use is for the treatment or prevention of a lysosomal storage disease which is Gaucher’s disease.